

ACCEL LIMITED

(Formerly known as Accel Transmatic Limited)



AL/NRP/BSE/002/2019-20

August 14, 2019

Manager - Corporate Relationship
Dept of Corporate Services
The Bombay Stock Exchange Limited
Floor 25, P.J. Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Intimation of Re-appointment of Independent Directors for the second term.
Re: SCRIP Code: 517494

Pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015, this is to inform you that the Board of Directors in the meeting held on 14th August 2019 have approved the following.

- a. Re-appointment of Dr. C.N. Ramchand (DIN: 05166709) Independent Director (whose current tenure will end on 09th November 2019) for a second term of three years subject to approval of members at the ensuing Annual General Meeting.
- b. Re-appointment of Dr. M. Ayyappan (DIN: 0007374) Independent Director (whose current tenure will end on 09th November 2019) for a second term of three years subject to approval of members at the ensuing Annual General Meeting.

The details as required under the SEBI (LODR) Regulations 2015 and SEBI Circular are enclosed herewith.

Kindly arrange to take the same on record.

Thanking you,

Yours faithfully,
For **Accel Limited**

N.R. Panicker
Managing Director
(DIN:00236198)

Enc: a.a

Annexure

Particulars	Dr. C.N.Ramchand	Dr. M. Ayyappan
Reasons for change viz. appointment, resignation, removal, death or otherwise	<p>Dr. C.N. Ramchand was appointed as Independent Director by the Company for a period of three years with effect from 10th November 2016 and subsequently approved by the shareholders in the Annual General Meeting held on 28th September 2017. His present term will end on 09.11.2019.</p> <p>The Board approved the reappointment of Dr. C.N. Ramchand as an Independent Director of the Company for a period of three years w.e. 28th September 2019 subject to the approval of shareholders' in the ensuing Annual General Meeting.</p>	<p>Dr. M. Ayyappan was appointed as Independent Director by the Company for a period of three years with effect from 10th November 2016 and subsequently approved by the shareholders in the Annual General Meeting held on 28th September 2017. His present term will end on 09.11.2019.</p> <p>The Board approved the reappointment of Dr. C.N. Ramchand as an Independent Director of the Company for a period of three years w.e. 28th September 2019 subject to the approval of shareholders' in the ensuing Annual General Meeting.</p>
Date of appointment/cessation (as applicable) & term of appointment	The second term as an Independent Director of the company of Dr. C.N. Ramchand will commence from 28 th September 2019 for a period of three years ending on 27 th September 2022 subject to the approval of shareholders' in the ensuing Annual General Meeting.	The second term as an Independent Director of the company of Dr. C.N. Ramchand will commence from 28 th September 2019 for a period of three years ending on 27 th September 2022 subject to the approval of shareholders' in the ensuing Annual General Meeting.
Brief profile in case of appointment	<p>Dr. C.N. Ramchand, a British Citizen, is currently the President and CEO of Saksin Life Sciences Pvt. Ltd, and MagGenome Technologies Pvt Ltd a start-up biotech company and Advisor to SciGenom Research Foundation, MedGenome Pvt Ltd and SciGenome Pvt Ltd.</p> <p>Dr. C.N. Ramchand was closely involved in the setting up of a multimillion Drug Discovery centre including design and development of laboratories.</p>	Dr. M. Ayyappan is Former Chairman and Managing Director of HLL Lifecare Limited and a Visionary, strategist, capable of building great institutions of rapid growth and sustainable wealth creation
Disclosure of relationships (in case of appointment of a director)	Nil	Nil